Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics

@article{Scher2011AdaptiveCT,
  title={Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics},
  author={Howard I. Scher and Shelley Fuld Nasso and Eric H. Rubin and Richard M. Simon},
  journal={Clinical Cancer Research},
  year={2011},
  volume={17},
  pages={6634 - 6640}
}
A critical challenge in the development of new molecularly targeted anticancer drugs is the identification of predictive biomarkers and the concurrent development of diagnostics for these biomarkers. Developing matched diagnostics and therapeutics will require new clinical trial designs and methods of data analysis. The use of adaptive design in phase III trials may offer new opportunities for matched diagnosis and treatment because the size of the trial can allow for subpopulation analysis. We… 
Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design
Biomarker based clinical trial design.
  • R. Simon
  • Biology, Medicine
    Chinese clinical oncology
  • 2014
TLDR
Clinical trial designs for the development of new therapeutics and predictive biomarkers to inform their use are reviewed, covering designs for a wide range of settings.
Biomarker based clinical trial design
TLDR
Clinical trial designs for the development of new therapeutics and predictive biomarkers to inform their use are reviewed, covering designs for a wide range of settings.
Advancing Clinical Trials to Streamline Drug Development
TLDR
The last decade in oncology has been marked by the identification of numerous new potential cancer targets and even more agents designed to inhibit them, and many challenges remain, including the lack of predictability of preclinical data for clinical results and phase II data for phase III results.
Clinical trials for precision oncology using next-generation sequencing.
TLDR
The demonstrated genomic heterogeneity of human cancers is having major impacts on the development and evaluation of cancer therapeutics and molecular diagnostics and the clinical studies that are being undertaken to translate genomics to clinical oncology are reviewed.
Run-in phase III trial design with pharmacodynamics predictive biomarkers.
  • F. Hong, R. Simon
  • Medicine, Biology
    Journal of the National Cancer Institute
  • 2013
TLDR
A new design for phase III trials with a candidate predictive pharmacodynamic biomarker measured after a short run-in period is introduced and achieves a major sample size reduction compared with the conventional randomized phase III design.
Biomarker adaptive designs in clinical trials
TLDR
This review is concerned with statistical aspects in the biomarker adaptive design for randomized clinical trials, which include the interaction test to identify predictive biomarkers, subgroup analysis, multiple testing and false discovery rate (FDR), classification of imbalanced class size data, sample size and power, and validation of the classification model.
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
As diagnostic tests become increasingly important for optimizing the use of drugs to treat cancers, the co-development of a targeted therapy and its companion diagnostic test is becoming more
Mouse tumour models to guide drug development and identify resistance mechanisms
TLDR
A review of the use of different types of preclinical tumour models to evaluate novel anticancer agents, and model the rapidly evolving landscape of resistance to targeted therapy.
Adaptive enrichment designs for clinical trials.
TLDR
A class of adaptive enrichment designs that allow the eligibility criteria of a trial to be adaptively updated during the trial, restricting entry to patients likely to benefit from the new treatment are proposed.
...
...

References

SHOWING 1-10 OF 41 REFERENCES
Clinical trials for predictive medicine: new challenges and paradigms
TLDR
A prediction based approach to the analysis of randomized clinical trials that both preserves the type I error and provides a reliable internally validated basis for predicting which patients are most likely or unlikely to benefit from the new regimen is outlined.
The Cross-Validated Adaptive Signature Design
TLDR
A cross-validation extension of the adaptive signature design is proposed that optimizes the efficiency of both the classifier development and the validation components of the design, and is applied to data from a randomized breast cancer trial.
Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients
TLDR
A new adaptive design for randomized clinical trials of targeted agents in settings where an assay or signature that identifies sensitive patients is not available at the outset of the study is proposed, which substantially reduces the chance of false rejection of effective new treatments.
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
TLDR
A statistically valid test for a biomarker-defined subset effect can be prospectively incorporated into a randomized phase III design without compromising the ability to detect an overall effect if the intervention is beneficial in a broad population.
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
  • S. Mandrekar, D. Sargent
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
This work discusses and evaluates various clinical trial designs for the validation of biomarker-guided therapy and suggests that well-designed retrospective analysis from well-conducted prospective RCTs can bring forward effective treatments to marker-defined subgroups of patients in a timely manner.
The Use of Genomics in Clinical Trial Design
  • R. Simon
  • Medicine, Biology
    Clinical Cancer Research
  • 2008
TLDR
Some designs for phase III clinical trials that may facilitate movement to a more predictive oncology and develop incentives for industry to incur the complexity and expense of codevelopment of drugs and companion diagnostics are reviewed.
Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy
TLDR
A hypothetical prospective observational study in non–small cell lung cancer that could serve as a model for patient-initiated study participation applied to understand molecular determinants of treatment response is described.
I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
I‐SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic
Identification and Elucidation of the Biology of Adverse Events: The Challenges of Safety Assessment and Translational Medicine
TLDR
The development of a U.S. Food and Drug Administration guidance document on the use of system biology in clinical testing would greatly benefit the development of drugs for oncology by communicating the potential application of specific methodologies, providing a framework for qualification and application of systems biology outcomes, and providing insight into the challenges and limitations of systems Biology in the regulatory decision-making process.
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
TLDR
The genomic technology brings a possible avenue for developing a genomic biomarker to predict a genomically responsive patient subset that may have a (much) higher likelihood of benefiting from a treatment.
...
...